An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Conditions:   Large B-cell Lymphoma;   B-cell Lymphoma Interventions:   Drug: Magrolimab;   Drug: Rituximab;   Drug: CAR T leukapheresis;   Drug: Radiation Sponsor:   M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials